Your prediction
Pros and Cons of Genetic Technologies Ltd. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genetic Technologies Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| TALI Digital Ltd. | -98.330% | 0.000% | -99.444% | 0.000% | -98.529% | 0.000% | -97.727% |
| Invion Ltd | 0.000% | 0.000% | 0.000% | -41.667% | -47.500% | 4100.000% | 320.000% |
| Immutep LTD ADR | -5.710% | 1.227% | -16.244% | -77.852% | -87.308% | -82.813% | -89.073% |
News
Pelthos Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Pelthos Therapeutics Inc.? Here are five stocks we like better.
- ZELSUVMI momentum continued: Second-quarter net product revenue rose 45% sequentially to $15.4 million
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch